Use of hormone replacement therapy before and after ovarian cancer diagnosis, and ovarian cancer survival

International Journal of Cancer

Volumn 119, Issue 12, 2006, Pages 2907-2915

  Mascarenhas, Chantal ^a,b   Lambe, Mats ^a   Bellocco, Rino ^a,c   Bergfeldt, Kjell ^d   Riman, Tomas ^e,f   Persson, Ingemar ^a,g   Weiderpass, Elisabete ^a,h  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e FALUN HOSPITAL   (Sweden)

^f Center for Clinical Research   (Sweden)

^g MEDICAL PRODUCTS AGENCY   (Sweden)

^h CANCER REGISTRY OF NORWAY   (Norway)

Author keywords

Hormonal replacement therapy; Mortality; Ovarian cancer; Survival; Sweden

Indexed keywords

CONJUGATED ESTROGEN; DIENESTROL; ESTRADIOL; ESTRIOL; ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SWEDEN;

AGED; CASE-CONTROL STUDIES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; SWEDEN; TIME FACTORS;

EID: 33751555272     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22218     Document Type: Article

References (31)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-41.
2. Gertig D, Hunter D. Ovarian cancer. In: Adami HO, Hunter D, Trichopoulos D, eds. Cancer epidemiology. Oxford: Oxford University Press, 2002. 378-99.
3. Speroff L, Glass RH, Kase NG. Menopause and postmenopausal hormone therapy. In: Speroff L, Glass RH, Kase NG, eds. Clinical gynecologic endocrinology and infertility. Baltimore: Williams and Wilkins, 1994. 583-649.
4. Weiderpass E, Baron JA, Adami HO, Magnusson C, Lindgren A, Bergstrom R, Correia N, Persson I. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 1999;353:1824-8.
5. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin- replacement therapy. Int J Cancer 1999;81:339-44.
6. Hankinson S, Hunter D. Breast cancer. In: Adami HO, Hunter D, Trichopoulos D, eds. Cancer epidemiology. Oxford: Oxford University Press, 2002. 301-39.
7. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002;288:321-33.
8. IARC monographs on the evaluation of carcinogenic risks to humans. Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy, Vol. 91. Lyon: IARC, in press.
9. Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergstrom R, Lindgren A, Correia N, Persson I. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131-7.
10. Persson I, Adami HO. Endometrial cancer. In: Adami HO, Hunter D, Trichopoulos D, eds. Cancer epidemiology. Oxford: Oxford University Press, 2002:359-77.
11. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Weiderpass E, Persson IR. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002;94:497-504.
12. Riman T. Hormone replacement therapy and epithelial ovarian cancer: is there and association? J Br Menopause Soc 2003;9:61-8.
13. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women's health initiative randomized trial. JAMA 2003;289:3243-53.
14. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. JAMA 2004;291:1701-12.
15. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002;360:942-4.
16. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002;288:49-57.
17. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR. Women's health initiative investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-80.
18. Eeles RA, Tan S, Wiltshaw E, Fryatt I, A'Hern RP, Shepherd JH, Harmer CL, Blake PR, Chilvers CE. Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 1991;302:259-62.
19. Rodriguez C, Calle EE, Coates RJ, Miracle-McMahill HL, Thun MJ, Heath CW, Jr. Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol 1995;141:828-35.
20. Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer 1999;86:1013-8.
21. Bebar S, Ursic-Vrscaj M. Hormone replacement therapy after epithelial ovarian cancer treatment. Eur J Gynaecol Oncol 2000;21:192-6.
22. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001;285:1460-5.
23. Ursic-Vrscaj M, Bebar S, Zakelj MP. Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause 2001;8:70-5.
24. Statistics - health and diseases. Cancer incidence in Sweden 2000. The National Board of Health and Welfare, Centre for Epidemiology: Stockholm, 2002.
25. Bendel RB, Afifi AA. Comparison of stopping rules in forward regression. J Am Stat Assoc 1977;72:46-53.
26. Therneau TM, Grambsch PM, Fleming TR. Martingale-based residuals for survival models. Biometrika 1990;77:147-60.
27. Riman T, Nilsson S, Persson IR. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand 2004;83:783-95.
28. DiSaia PJ. Hormone replacement therapy in the gynecologic and breast cancer patient. Cancer Control 1996;3:101-6.
29. Sorbe B, Frankendal B. Ovarian cancer [Swedish]. In: Sorbe B, Frankendal B, eds. Gynecologic oncology. Lund: Studentlitteratur, 2000, 283-308.
30. Michaelsson K, Baron JA, Farahmand BY, Johnell O, Magnusson C, Persson PG, Persson I, Ljunghall S. Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ 1998;316:1858-63.
31. Bray F, Loos AH, Tognazzo S, La Vecchia C. Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Int J Cancer 2005;113:977-90.